Propranolol Enantiomers - Chirality in Pharmacology

Introduction

Propranolol was the first clinically successful beta-blocker, revolutionizing the treatment of heart disease and anxiety. Its inventor, Sir James Black, won the Nobel Prize in Medicine in 1988.

Structure Comparison

Both enantiomers share the formula C₁₆H₂₁NO₂. The structure features a naphthalene ring connected via an ether linkage to an amino alcohol - the pharmacophore common to all beta-blockers.

Chiral Center

The chiral center is the carbon bearing the hydroxyl group in the amino alcohol side chain. It carries four different groups: -OH, -H, the naphthyloxymethyl chain, and the isopropylamino group.

Pharmacological Differences

S-propranolol binds the beta-1 and beta-2 adrenergic receptors about 100 times more tightly than R-propranolol. The hydroxyl group on the chiral center forms a critical hydrogen bond with the receptor.

Clinical Impact

Despite the 100-fold potency difference, propranolol is sold as a racemate. R-propranolol is essentially inert at beta receptors and causes no harmful effects, so there is no safety reason to resolve the enantiomers.

Key Takeaway

Propranolol demonstrates that a large potency difference between enantiomers does not always require enantiopure formulation. If the less active form is harmless, selling the racemate is simpler and cheaper.

Related Topics